Corcept Therapeutics Inc (NASDAQ:CORT) Director G Leonard Baker, Jr. bought 103,386 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was purchased at an average cost of $2.32 per share, for a total transaction of $239,855.52. Following the completion of the transaction, the director now directly owns 578,389 shares of the company’s stock, valued at approximately $1,341,862. Corcept Therapeutics Incorporated (NASDAQ:CORT) stock performance was -5.04% in last session and finished the day at $2.45. Traded volume was 392,568.00million shares in the last session and the average volume of the stock remained 675.90K shares. The beta of the stock remained 1.55. Corcept Therapeutics Incorporated (NASDAQ:CORT) insider ownership is 2.60%.

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for OGXI broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) dropped -5.63 percent to $3.35 Friday on volume of 411,557.00million shares. The intra-day range of the stock was $3.32 to $3.54. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) has a market capitalization of $49.42million.

Anika Therapeutics Inc. (NASDAQ:ANIK) has been losing ground since the open of trade Friday and is now down 2.50 at $44.87. Trading volume has begun to accelerate in the past 15 minutes. Anika Therapeutics has been pulling back from the highs of the year for the past 3 sessions and has dropped to over a 1-month low. On Friday, shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) dropped -5.28% to close the day at $44.87. Company return on investment (ROI) is 15.30% and its monthly performance is recorded as -3.40%. Anika Therapeutics, Inc. (NASDAQ:ANIK) quarterly revenue growth is 5.83%.

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), today discussed the vantictumab (anti-Fzd7, OMP-18R5) and Fzd8-Fc (OMP-54F28) Phase 1 Wnt pathway programs with the U.S. Food and Drug Administration (FDA). The FDA informed the company that a partial clinical hold has been placed on Phase 1 clinical trials of vantictumab until revised protocols have been submitted and concurred with. Oncomed Pharmaceuticals Inc (NASDAQ:OMED)’s stock on June 13, 2014 reported a decrease of -8.80% to the closing price of $22.71. Its fifty two weeks range is $12.06 -$42.34. The total market capitalization recorded $671.04million. The overall volume in the last trading session was 903,074.00million shares. In its share capital, OMED has 29.56million outstanding shares.

Cesca Therapeutics Inc (NASDAQ: KOOL) 17.5% LOWER; announced the pricing of an underwritten public offering of 7,530,000 Units, consisting of an aggregate of 7,530,000 shares of the Company’s common stock and warrants to purchase 2,259,000 shares of the Company’s common stock, at a price of $1.50 per Unit. Each warrant entitles the holder to purchase 0.30 of a share of common stock. The warrants will be exercisable immediately upon issuance at an exercise price of $1.55 per share and will expire five years from the date of issuance. Cesca Therapeutics Inc (NASDAQ:KOOL) stock performance was -17.51% in last session and finished the day at $1.46. Traded volume was 1.25million shares in the last session and the average volume of the stock remained 461.89K shares. The beta of the stock remained 1.18. Cesca Therapeutics Inc (NASDAQ:KOOL) insider ownership is 30.50%.